End-of-day quote
Korea S.E.
03:30:00 24/05/2024 am IST
|
5-day change
|
1st Jan Change
|
6,140
KRW
|
-0.65%
|
|
-1.92%
|
+24.04%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
76,121
|
82,062
|
1,45,429
|
78,193
|
51,626
|
35,741
|
Enterprise Value (EV)
1 |
77,195
|
1,03,090
|
1,57,584
|
92,940
|
81,227
|
67,910
|
P/E ratio
|
11.4
x
|
200
x
|
-12.9
x
|
-7.1
x
|
-56.6
x
|
-1.97
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.39
x
|
1.6
x
|
2.89
x
|
1.62
x
|
0.84
x
|
0.57
x
|
EV / Revenue
|
1.41
x
|
2.01
x
|
3.13
x
|
1.92
x
|
1.33
x
|
1.08
x
|
EV / EBITDA
|
7.99
x
|
31.6
x
|
-22.2
x
|
-14.5
x
|
15.4
x
|
-6.29
x
|
EV / FCF
|
-9.78
x
|
-7.34
x
|
-41.2
x
|
11.8
x
|
-6.08
x
|
-9.02
x
|
FCF Yield
|
-10.2%
|
-13.6%
|
-2.43%
|
8.47%
|
-16.5%
|
-11.1%
|
Price to Book
|
1.35
x
|
1.41
x
|
2.13
x
|
1.47
x
|
1.06
x
|
1.18
x
|
Nbr of stocks (in thousands)
|
5,745
|
5,904
|
7,904
|
7,704
|
7,220
|
7,220
|
Reference price
2 |
13,250
|
13,900
|
18,400
|
10,150
|
7,150
|
4,950
|
Announcement Date
|
19/03/19
|
16/03/20
|
23/03/21
|
23/03/22
|
23/03/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
54,662
|
51,264
|
50,379
|
48,304
|
61,293
|
63,169
|
EBITDA
1 |
9,659
|
3,266
|
-7,084
|
-6,389
|
5,266
|
-10,792
|
EBIT
1 |
7,768
|
791.3
|
-10,832
|
-10,615
|
1,271
|
-14,682
|
Operating Margin
|
14.21%
|
1.54%
|
-21.5%
|
-21.97%
|
2.07%
|
-23.24%
|
Earnings before Tax (EBT)
1 |
6,854
|
586.3
|
-12,084
|
-14,477
|
943.5
|
-14,404
|
Net income
1 |
5,828
|
411.2
|
-9,322
|
-11,109
|
-932
|
-18,156
|
Net margin
|
10.66%
|
0.8%
|
-18.5%
|
-23%
|
-1.52%
|
-28.74%
|
EPS
2 |
1,158
|
69.53
|
-1,431
|
-1,430
|
-126.3
|
-2,514
|
Free Cash Flow
1 |
-7,896
|
-14,054
|
-3,824
|
7,871
|
-13,368
|
-7,528
|
FCF margin
|
-14.44%
|
-27.41%
|
-7.59%
|
16.3%
|
-21.81%
|
-11.92%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/19
|
16/03/20
|
23/03/21
|
23/03/22
|
23/03/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
1,074
|
21,028
|
12,155
|
14,747
|
29,601
|
32,169
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.1111
x
|
6.439
x
|
-1.716
x
|
-2.308
x
|
5.622
x
|
-2.981
x
|
Free Cash Flow
1 |
-7,896
|
-14,054
|
-3,824
|
7,871
|
-13,368
|
-7,528
|
ROE (net income / shareholders' equity)
|
14.1%
|
0.71%
|
-14.7%
|
-18.2%
|
-1.82%
|
-46%
|
ROA (Net income/ Total Assets)
|
6.66%
|
0.54%
|
-6.99%
|
-6.14%
|
0.69%
|
-8.87%
|
Assets
1 |
87,464
|
75,720
|
1,33,307
|
1,81,048
|
-1,35,804
|
2,04,737
|
Book Value Per Share
2 |
9,792
|
9,833
|
8,650
|
6,925
|
6,733
|
4,196
|
Cash Flow per Share
2 |
2,131
|
880.0
|
197.0
|
2,733
|
833.0
|
910.0
|
Capex
1 |
5,479
|
16,017
|
7,844
|
7,168
|
3,366
|
2,263
|
Capex / Sales
|
10.02%
|
31.24%
|
15.57%
|
14.84%
|
5.49%
|
3.58%
|
Announcement Date
|
19/03/19
|
16/03/20
|
23/03/21
|
23/03/22
|
23/03/23
|
21/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +24.04% | 3.27Cr | | +16.41% | 7.96TCr | | +8.35% | 878.59Cr | | +47.36% | 472.79Cr | | +1.74% | 391.9Cr | | +14.51% | 227.7Cr | | -26.23% | 220.05Cr | | +15.63% | 211.12Cr | | -34.87% | 207.91Cr | | -0.50% | 164.41Cr |
Specialty & Advanced Pharmaceuticals
|